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Abstract
Apocrine-eccrine carcinomas are rare and associated with poor prognosis. Currently there is no uniform treatment
guideline. Chemotherapeutic drugs that selectively target cancer-promoting pathways may complement conventional
therapeutic approaches. However, studies on genetic alterations and EGFR and Her2 status of apocrine-eccrine carcinomas
are few in number. In addition, hormonal studies have not been comprehensive and performed only on certain subsets of
apocrine-eccrine carcinomas. To investigate whether apocrine-eccrine carcinomas express hormonal receptors or possess
activation of oncogenic pathways that can be targeted by available chemotherapeutic agent we performed
immunohistochemistry for AR, PR, ER, EGFR, and HER2 expression; fluorescence in situ hybridization (FISH) for EGFR and
ERBB2 gene amplification; and molecular analyses for recurrent mutations in 15 cancer genes including AKT-1, EGFR, PIK3CA,
and TP53 on 54 cases of apocrine-eccrine carcinomas. They include 10 apocrine carcinomas, 7 eccrine carcinomas, 9
aggressive digital papillary adenocarcinomas, 10 hidradenocarcinomas, 11 porocarcinomas, 1 adenoid cystic carcinoma, 4
malignant chondroid syringomas, 1 malignant spiradenoma, and 1 malignant cylindroma. AR, ER, PR, EGFR and HER2
expression was seen in 36% (19/53), 27% (14/51), 16% (8/51), 85% (44/52) and 12% (6/52), respectively. Polysomy or trisomy
of EGFR was detected by FISH in 30% (14/46). Mutations of AKT-1, PIK3CA, and TP53 were detected in 1, 3, and 7 cases,
respectively (11/47, 23%). Additional investigation regarding the potential treatment of rare cases of apocrine-eccrine
carcinomas with PI3K/Akt/mTOR pathway inhibitors, currently in clinical testing, may be of clinical interest.
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Introduction
In a recent World Health Organization (WHO) classification of
cutaneous appendageal carcinomas; apocrine-eccrine, follicular,
and sebaceous carcinomas were the three main categories cited in
the consensus classification after taking into account the clinical,
histologic, and molecular genetic features [1]. Apocrine-eccrine
carcinomas are rare and associated with poor prognosis [2–4].
Three of nine cases of clear cell eccrine carcinomas reported by
Wong et al. [4] developed metastases despite local excision,
radiation, and chemotherapy. In the largest series of 69 cases of
porocarcinomas by Robson et al. [3], 17% and 19% experienced
local recurrence and lymph node metastases, respectively. In
recent Surveillance, Epidemiology, and End Results (SEER)
Program of the National Cancer Institute data from 1978 through
2005, the incidence rate of apocrine-eccrine carcinomas was
reported to be 2.6 per 1 million person-years [2]. The five-year
relative survival rates for apocrine-eccrine carcinomas were 99%
for localized, 94% for regional and 51% for distant disease [2].
Due to the frequent tendency for recurrence (50%) and
potential to metastasize (14%), amputation of the digit is often
the treatment for aggressive digital papillary adenocarcinoma [5].
For the remaining apocrine-eccrine carcinomas, wide surgical
excision is also the treatment of choice. Currently there is no
uniform guideline concerning the treatment for various types of
apocrine-eccrine carcinomas, especially for those with metastases.
Treatment success for metastatic disease has been documented
only in isolated case reports of metastasizing hidradenocarcinomas
and eccrine carcinoma [6–8].
Targeted therapy may be a potential treatment option in
patients whose tumors are characterized by a relevant oncogene
mutation [4,9,10]. In a growing number of tumor types including
breast, colorectal and lung cancer, selective agents that target
critical cancer-promoting pathways are now the treatment of
choice for those patients carrying the genetic changes recognized
by the drugs [4,9,10]. Members of the ERBB receptor tyrosine
kinase family, including epidermal growth factor receptor (EGFR),
HER2, HER3 and HER4, also present possible targeted
therapeutic options [11]. ERBB2 (v-erb-b2 erythroblastic leukemia
viral oncogene homolog 2) gene amplification and response to
trastuzumab were documented in a case of metastasizing
hidradenocarcinoma [7]. The membranous expression of these
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e47290markers has therapeutic implications and second-generation
epidermal growth factor receptor tyrosine kinase inhibitors such
as HKI-272, XL647, and BIBW2992 have dual activity, inhibiting
both EGFR and HER2 receptors [12,13]. Targeting the hormone
receptor pathway may also represent one potential therapeutic
approach [14].
With the exception of the tumors associated with familial
syndromes, studies on genetic alterations [15–19] and biomarkers
such as epidermal growth factor receptor (EGFR) and HER2
status [7,17,20] of apocrine-eccrine carcinomas are few in
number. Translocation t(11;19) has been demonstrated in 2 of
11 hidradenocarcinomas [17]. In addition, hormonal studies have
not been comprehensive and performed only on certain subsets of
apocrine-eccrine carcinomas [7,21–23].
We have previously reported mutations of PIK3CA and TP53 in
2 and 3 tumors, respectively, in a series of 14 metastasizing
apocrine-eccrine carcinomas [16]. Only one case of aggressive
digital papillary adenocarcinoma was included in that study. In
addition, subtypes such as adenoid cystic carcinoma, malignant
chondroid syringoma, malignant spiradenoma, and malignant
cylindroma were not included in our previous series [16]. To
investigate whether apocrine-eccrine carcinomas express hormon-
al receptors or possess activation of oncogenic pathways that could
be targeted by available chemotherapeutic agent we performed
immunohistochemistry for AR, ER, PR, EGFR, and HER2
expression; fluorescence in situ hybridization (FISH) for EGFR and
ERBB2 gene amplification; and single base extension genotyping
[24] for recurrent mutations in 15 cancer genes including AKT-1,
EGFR, PIK3CA, and TP53 on an expanded series of 54 cases of
apocrine-eccrine carcinomas (Table 1).
Materials and Methods
This study has been approved by the Massachusetts General
Hospital institutional review board (IRB No. 2011-P-2489). Since
the study is limited to the use of excess human material and health
related information, written consent was exempted by IRB.
Archival materials of all cutaneous apocrine-eccrine carcinomas
including apocrine carcinoma, eccrine carcinoma, aggressive
digital papillary adenocarcinoma, hidradenocarcinoma, malignant
spiradenoma, porocarcinoma, adenoid cystic carcinoma, malig-
nant chondroid syringoma, and malignant cylindroma diagnosed
between 1987 and 2011 were retrieved from the pathology files of
the Massachusetts General Hospital, Boston, MA. In addition, the
personal consultation files of MCM from 2006–2011 was
searched. Age, gender, tumor site, tumor size and clinical
follow-up information (such as local recurrence or metastasis)
were extracted from the patients’ medical records. All patient data
were de-identified. The histologic sections of all cases were re-
examined and the diagnoses were confirmed.
Immunohistochemistry
Immunohistochemical studies were performed on five-microm-
eter-thick sections of formalin-fixed, paraffin-embedded tissue,
using the standard techniques involving heat-induced epitope
retrieval buffer, and primary antibodies against AR (M3562, 1:50,
Dako, Carpinteria, CA), ER (SP1, prediluted, Ventana Medical
Systems, Tucson, AZ), PR (1E2, prediluted, Ventana Medical
Systems), EGFR (3C6, prediluted, Ventana Medical Systems), and
HER2 (4B5, prediluted, Ventana Medical Systems). Appropriate
positive and negative controls were included.
Nuclear expression of AR, ER and PR were graded as
percentage of positive cells: 0%=0, 1–10% =1+, 11–25%
=2+, 26–50% =3+, and 51–100% =4+. Evaluation of mem-
branous EGFR expression was performed using a combined
scoring system based on both the staining intensity (0=no
staining, 1=weak, 2=moderate, 3=strong staining) as well as
the percentage of positive cells (0% =0, ,25% =1, 26–50% =2,
51–75% =3, .75% =4), similar to that outlined by Janisson-
Dargaud et al [25]. The sum of these 2 scores yielded a total score
from 0 to 7 (1–3=weak, 4–7=strong). Overexpression of HER2
was defined as positive membranous staining in more than 10% of
the neoplastic cells. Partial and faint, weak or thin, and intense or
thick circumferential membrane staining in more than 10% of the
tumor cells were scored as 1+(negative), 2+ (equivocal), and 3+
(positive), respectively.
Mutational Analysis and EGFR and ERBB2 Fluorescence in
situ Hybridization (FISH)
A SNaPshotH genotyping assay recently developed by our group
was performed on 50 tumors with available archival materials
[24]. This assay consists of multiplexed PCR followed by a single-
base extension reaction and uses the commercially available
SNaPshot platform (Applied Biosystems). The original tumor
genotyping panel described by Dias-Santagata et al [24], was
expanded to include three additional assays (AKT1.49, testing for
the AKT1 E17K mutation; and IDH1.394 and IDH1.395, testing
for hotspot mutations in IDH1, which affect codon R132). The full
panel is outlined in Table 1 and tests for common mutations in 15
cancer genes. SNaPshotH genotyping was performed using pre-
viously described conditions [24], and included the following
additional primers for AKT1 and IDH1 (PCR: AKT1 exon 3
Forward, 59-ACGTTGGATGGGTA-
GAGTGTGCGTGGCTCT-39; AKT1 exon 3 Reverse, 59-
ACGTTGGATGAGGTGCCATCATTCTTGAGG-39; IDH1
exon 4 Forward, 59-ACGTTGGATGGGCTTGTGAGTG-
GATGGGTA-39, IDH1 exon 4 Reverse 59- ACGTTGGATGG-
CAAAATCACATTATTGCCAAC-39. Extension: AKT1.49 extR
59- CTGACTGACTGACTGACTGACTGACTGACTGACT-
GACTGACTGACTGACTGACTGACTGACTGACTGACT-
GAGCCAGGTCTTGATGTACT-39IDH1.394 extR 59-GACT-
GACTGGACTGACTGACTGACTGACTGGACTGACT-
GACTGAGATCCCCATAAGCATGAC-39, IDH1.395 extR 59-
TGATCCCCATAAGCATGA-39).
EGFR gene copy number was assessed in 49 tumors by
fluorescence in situ hybridization (FISH) as previously published
[26]. FISH failed in 3 tested cases. Gene amplification and
polysomy were defined per criteria outlined by Cappuzzo et al
[27]. ERBB2 gene copy number was also assessed in 6 cases with
2+ HER2 protein overexpression. Polysomy 7 was defined as three
or more CEP signals per cell.
Statistical Analysis
For patients with follow-up data available, metastasis-free
survival time was calculated as time from diagnosis to identifica-
tion of metastatic disease in the lymph nodes or distant organs.
Patients who did not develop metastases were considered censored
at the time of most recent follow-up report. Log-rank tests were
used to compare the distribution of metastasis-free survival
between subgroups defined by positivity for mutational status
(defined as non-wild type for one or more genes tested); EGFR
FISH; AR, ER, PR, EGFR, and HER2 expression. Kaplan-Meier
plots were created to visually assess the differences in metastasis-
free survival among subgroups. The statistical association of AR
expression in apocrine versus eccrine carcinoma was analyzed by
Fisher’s Exact Test. A two-tailed p value of less than 0.05 was
considered to be statistically significant.
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A total of 54 cases were identified: apocrine carcinoma (10),
eccrine carcinoma (7), aggressive digital papillary adenocarcinoma
(9), hidradenocarcinoma (10), porocarcinoma (11), adenoid cystic
carcinoma (1), malignant chondroid syringoma (4), malignant
spiradenoma (1), and malignant cylindroma (1).
The age of the patients ranged from 22 to 94 years (median,
62 years). The male to female ratio was 1:1. The locations of
the tumors include: head and neck region (19), axilla (3), finger
(9), hand (1), trunk (10), lower extremity (3), foot (3), vulva (4),
and lymph node metastases (2). Six patients received radiation
therapy (3 with porocarcinomas, 1 aggressive digital papillary
adenocarcinoma, 1 eccrine carcinoma and 1 apocrine carcino-
ma) and one patient with aggressive digital papillary adenocar-
cinoma received 6 cycles of Carbol/taxol chemotherapy.
Follow-up was available for 38 patients (range, 0–11.4 years;
median: 2.6 years). Four cases (one apocrine carcinoma, one
eccrine carcinoma, and two porocarcinomas) developed recur-
rences. Metastases developed in 15 (39%) patients (4 with
apocrine carcinoma, 6 eccrine carcinoma, 2 porocarcinomas, 2
aggressive digital papillary adenocarcinomas, and 1 hidradeno-
carcinoma) (Table 2). Widespread metastases developed in one
patient with eccrine carcinoma that resulted in death (Table 2).
Table 1. SNaPshotH mutational assays [24].
Gene Amino Acid – cDNA residue Gene
Amino Acid –
cDNA residue
v-akt murine thymoma viral oncogene
homolog1 (AKT1)
E17–49G NOTCH1 L1575–4724T
Adenomatous polyposis coli (APC) R1114–3340C L1601–4802T
Q1338–4012C Neuroblastoma RAS viral (v-ras)
oncogene homolog (NRAS)
G12–34G
R1450–4348C G12–35G
T1556fs* - 4666_4667insA G13–37G
v-raf murine sarcoma viral oncogene
homolog B1 (BRAF)
V600–1798G G13–38G
V600–1799T Q61–181C
Catenin (cadherin-associated protein),
beta 1, 88 kDa (CTNNB1)
D32–94G Q61–182A
D32–95A Q61–183A
S33–98C Phosphoinositide-3-kinase, catalytic,
alpha polypeptide (PIK3CA)
R88–263G
G34–101G E542–1624G
S37–109T E545–1633G
S37–110C Q546–1636C
T41–121A Q546–1637A
T41–122C H1047–3139C
S45–133T H1047–3140A
S45–134C G1049–3145G
Epidermal growth factor receptor (EGFR) G719–2155G Phosphatase and tensin homolog (PTEN) R130–388C
T790–2369C R173–517C
L858–2573T R233–697C
E746_A750–2235_2249del K267fs* - 800delA
E746_A750–2235_2250del Tumor protein 53 (TP53) R175–524G
Isocitrate dehydrogenase 1 (NADP+),
soluble (IDH1)
R132–394C G245–733G
R132–395G R248–742C
Fms-related tyrosine kinase 3 (FLT3) D835–2503G R248–743G
Janus kinase 3 (JAK2) V617–1849G R273–817C
v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene (KIT)
D816–2447A R273–818G
v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS)
G12–34G R306–916C
G12–35G
G13–37G
G13–38G
doi:10.1371/journal.pone.0047290.t001
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Immunohistochemistry was performed on 54 cases and the
results are summarized in Table 3. Forty three percent (23/53) of
cases expressed 1–4+ AR (Figures 1A and 1B). Thirty three
percent (17/51) of cases expressed 1–4+ ER. Twenty percent (10/
51) of apocrine-eccrine carcinomas expressed 1–4+ PR. Significant
p-value (p,0.0001 via Fisher’s exact test) was noted when
comparing AR-positivity in apocrine carcinoma versus eccrine
carcinoma. Overexpression of EGFR was seen in 44/52 (85%)
cases (Figures 2A and 2B), with 40 cases showing high and 4
cases showing low level of expression. HER overexpression (2+)
was seen in 6/52 (12%) cases. Metastasis-free survival did not
differ significantly by expression of AR, ER, PR, EGFR, or HER2
(p.0.05 for all comparisons).
Mutational Analysis and FISH
The molecular results are summarized in Table 4. We have
recently developed a multiplexed tumor genotyping clinical assay
that uses the SNaPshot platform from Applied Biosystems [24].
This assay performs well with archived tissue and tests for
recurrent mutations in 15 cancer genes, including potentially
actionable targets such as BRAF, EGFR, KRAS, PIK3CA, and TP53
(Table 1). The genes included in this panel were selected based on
their clinical significance and on the availability of therapeutic
agents (either FDA-approved or under clinical testing) targeting
these cancer pathways [24]. Due to poor quality DNA, the assay
completely failed in 3 cases. In 5 cases, only a portion of the assay
failed (see Appendix S1). SNaPshot genotyping identified somatic
mutations in 23% (n=11) of 47 cases (Figure 3). Activating
PIK3CA mutations were detected in 1 hidradenocarcinoma
(c.1624G.A; p.Glu542Lys) and 2 porocarcinomas (c.1624G.A;
p.Glu542Lys and c.1633G.A; p.Glu545Lys). TP53 mutations
were detected in 2 eccrine carcinomas (c.743G.A; p.Arg248Gln
and c.817C.T; p.Arg273Cys), 2 hidradenocarcinomas
(c.817C.T; p.Arg273Cys), 2 aggressive digital papillary adeno-
carcinoma (c.818G.A; p.Arg273His and c.817C.T;
p.Arg273Cys), and 1 malignant cylindroma (c.818G.A; p.Ar-
g273His). AKT-1 (E17K) mutation was detected in one hidrade-
nocarcinoma. Metastasis-free survival was not significantly asso-
ciated with mutational status (p=0.12, Figure 4).
FISH for EGFR gene amplification was successful in 46/50
cases. Either polysomy (Figure 2C) or trisomy was detected in
14/46 (30%) cases. Of these 14 cases, 4 (9%) exhibited high
polysomy of EGFR (defined as $4 copies in $40% of cells by
Capuzzzo et al [27]). Although 84% of cases overexpressed EGFR,
only 30% exhibited polysomy or trisomy and no cases showed
gene amplification. ERBB2 gene amplification was not detected in
any of the 6 cases with 2+ HER2 protein expression. Thus, there
appears to be no correlation between IHC and FISH in evaluating
both EGFR and ERBB2. There was no significant difference in
the distribution of metastasis-free survival time comparing patients
with detected polysomy/trisomy in EGFR FISH compared to
those without (p=0.6, Figure 5).
Discussion
It is known that apocrine-eccrine carcinomas often express
estrogen receptor and progesterone receptor [21,23]. Due to their
similar morphology and possible embryologic origin, it is not
surprising that ER, PR, and AR expression can be seen in
apocrine-eccrine carcinomas as observed in mammary carcinomas
[21–23,28,29]. ER expression was seen in 10/33 (30%) apocrine-
eccrine carcinomas in a series by Swanson et al [23] and the
positive tumors included 8 eccrine carcinomas, 1 porocarcinoma,
and 1 mucinous eccrine carcinoma. Twenty-one percent (9/42)
and nineteen percent (8/42) of primary sweat gland carcinomas
Table 2. Clinical data of the fifteen patients with apocrine-eccrine carcinomas and metastatic disease.
Age/
gender Tumor type Tumor site
Local
recurrence
Lymph node
metastasis
Distant
metastases Surgery Adjuvant therapy
1 45/F apocrine L axilla none axillary LN Spine LN dissection
2 69/F apocrine R vulva none 5/7 groin LN None bilateral LN
dissection
3 81/M apocrine axilla yes axillary LN None LN dissection radiotherapy
4 38/F apocrine vulva none L inguinal LN None LN dissection
5 68/F eccrine L foot none none R groin skin
6 62/M eccrine L lower leg none thoracic LN lung, liver, adrenal
glands
7 62/M eccrine L groin none 7/9 inguinal LN Skin bilateral LN
dissection
radiotherapy
5-Fluoracil and
cisplatinum
8 80/M eccrine L cheek none 3/9 neck LN None
9 81/M eccrine groin yes yes Skin
10 66/M eccrine L dorsal foot none yes Skin
11 51/M ADPA L index finger none L axillary LN Lung 6 cycles of Taxol/
Carbo
12 51/M ADPA L index finger none yes None
13 78/M hidradenocarcinoma R shoulder none 6/22 R axillary LN None LN dissection
14 78/F porocarcinoma L lower leg none 4/6 L inguinal LN Skin LN dissection radiotherapy
15 83/M porocarcinoma L ear yes yes None LN dissection radiotherapy
F: female, M: male, R: right, L: left, ADPA: aggressive digital papillary adenocarcinoma, LN: lymph node.
doi:10.1371/journal.pone.0047290.t002
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Similarly, in our series 33% (17/51) and 20% (10/51) of apocrine-
eccrine carcinomas expressed ER and PR, respectively. The
expression of hormonal receptors could have treatment implica-
tions since hormonal modulation plays an important role in the
prevention and treatment of breast carcinomas [14]. Choudhry
et al [30] reported AR expression in normal apocrine as well as
eccrine glands. This suggests that androgen may modulate the
function of both apocrine and eccrine glands. The expression of
steroid receptors in aggressive digital papillary adenocarcinomas
has not been studied. Of interest, all of the primary cutaneous
apocrine carcinomas (9/9, 100%) and a third of the aggressive
digital papillary adenocarcinomas express AR in more than 10%
of tumor cells in our current series. By contrast, none of the
eccrine tumors (0/7, 0%) in our series exhibited AR expression.
This suggests that AR-positivity is strongly correlated with pure
apocrine carcinoma morphology (p,0.0001). This raises the
potential of anti-androgen therapy for these subsets of apocrine-
eccrine carcinomas. Androgen deprivation therapy using bicalu-
tamide has been reported to be beneficial in the treatment of
metastasizing salivary duct carcinoma [31].
Strong (3+) overexpression of HER2 (3+) and gene amplification
have been documented in one case of metastasizing hidradeno-
carcinoma [7]. These findings suggested that ERBB2 may be
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Figure 1. Apocrine carcinoma. (A) Cribriform architecture, polygonal
neoplastic cells and eosinophilic cytoplasm are characteristic features of
apocrine carcinoma (X200). (B) Strong and diffuse nuclear staining for
androgen receptor is noted (X200).
doi:10.1371/journal.pone.0047290.g001
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carcinoma; however, we were unable to confirm this finding. None
of the six apocrine-eccrine carcinomas in our series with (2+)
HER2 overexpression demonstrated ERBB2 gene amplification.
This is consistent with prior published results indicating that high
level ERBB2 gene amplification is unlikely in the setting of 2+
HER2 overexpression [17].
Epidermal growth factor receptor (EGFR/erbB-1) belongs to
a receptor family with tyrosine kinase activity whose gene is
located on chromosome 7p12. The EGFR signaling that mediates
proliferation, migration, invasion, and suppression of apoptosis,
can be blocked by a growing number of inhibitor drugs. The role
of EGFR inhibitor therapy in apocrine-eccrine carcinomas with
protein overexpression remains unclear. Although the majority
(85%, 44/52) of apocrine-eccrine carcinomas in our series
demonstrated EGFR protein overexpression, only EGFR trisomy
or polysomy (13/47, 28%) and no gene amplification were
documented by FISH, most frequently noted in eccrine carcino-
ma, hidradenocarcinoma and porocarcinoma. This is not an
unexpected finding; since similar results were noted in our recent
study of hidradenocarcinomas [20]. In addition, other studies have
shown that EGFR overexpression appears to be independent of
EGFR mutation [32,33]. In lung and salivary gland carcinomas,
high polysomy of EGFR if considered to be FISH-positive and the
patients would receive treatment [34,35]. Further studies are
warranted to determine whether similar practice may be applied
for apocrine-eccrine carcinomas.
Tumor suppressor gene, TP53, located on the short arm of
chromosome 17p13 has been implicated in the regulation of cell
growth, DNA repair, and apoptosis. The TP53 gene is frequently
(14–52%) altered in human breast carcinomas and is the most
commonly mutated gene in human tumors [36–38]. TP53
mutations are usually clustered within the most conserved regions
of exons 4, 5, 7, and 8 [39]. TP53 mutations have been previously
described in apocrine-eccrine carcinomas (Table 5) [15–19].
Takata et al [18] performed PCR based assays for loss of
heterozygosity on chromosomes 3p, 5q, 9p, 9q, 13q, and 17p;
yet found only 1 case with TP53 mutation by direct sequencing of
exons 5 to 8. Biernat et al [15] employed single-stranded
conformation polymorphism analysis followed by direct DNA
sequencing and found 5 of 16 sweat gland carcinomas possessed
TP53 mutations (Table 5). Two of eleven hidradenocarcinomas
exhibited TP53 mutations in the series by Kazakoz et al. [17]
Similar to findings reported by Biernat et al [15] and Kazakov et al
[17], we found TP53 mutations in codon 248 of exon 7 and codon
273 of exon 8 in our 7 positive cases (Table 5). Interestingly, these
same mutations have also been reported in breast carcinomas [40–
42]. Although SnaPshot testing works well for oncogenes, which
are typically mutated at only a few distinct loci, it is not
comprehensive for tumor suppressors. It captures only a few of
the numerous mutation events described for TP53, at loci that are
not covered by the assay.
PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha poly-
peptide) mutations in these tumors have been reported by our
group [16]. In breast carcinomas, the majority of mutations have
been identified in the helical domain (exon 9, 37%) and in the
kinase domain (exon 20, 63%) of PIK3CA [43]. All mutations were
single-based substitutions [43]. Similarly we detected 2 types of
mutations, c.1624G.A:p.Glu542Lys (in one hidradenocarcinoma
and one porocarcinoma) and c.1633G.A:Glu545Lys (in one
porocarcinoma), in exon 9 of PIK3CA. These 2 mutations are
among the three most frequently reported mutations in breast
cancer [43]. Mutations in codon 545 represent a mutational
hotspot reported in ovarian and colorectal carcinomas as well
[44,45]. The clustering of mutations within PIK3CA may prove
useful for therapeutic purposes. The phosphatidylinositol 3 kinase
(PIK3) signaling pathway is an important regulator of cell growth,
proliferation, cell motility, angiogenesis, and survival, and it has
been shown that PIK3CA is the most frequently mutated gene in
Figure 2. Hidradenocarcinoma. (A) Cribriform necrosis and clear cell
change are seen in a hidradenocarcinoma (X40). (B) Strong membra-
nous expression of EGFR was noted (X200). (C) However, fluorescence in
situ hybridization revealed only balanced polysomy of chromosome 7
and EGFR gene (X1000).
doi:10.1371/journal.pone.0047290.g002
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oncogenic mutations in PIK3CA or low levels of PTEN expression
may confer resistance to treatment with trastuzumab, a mono-
clonal antibody that targets the HER2/Neu receptor [48]. ERBB2
amplification and PIK3CA mutation were validated as biomarkers
for sensitivity to the single-agent phosphoinositide 3-kinase (PIK3)
inhibitor, GDC-0941, in breast cancer models [49]. Other studies
have shown that cancers with PIK3CA mutations were sensitive to
single-agent PI3K inhibitors and dual PI3K-mammalian target of
rapamycin (mTOR) inhibitors [50,51].
AKT-1 mutation has not been previously described in cutaneous
appendageal carcinomas. In carcinomas, the PI3K/AKT pathway
is well characterized [46,52]; and the PI3K/Akt/mTOR pathway
has been shown to be a target for cancer therapy including breast
carcinoma [53]. While mutations in the PI3 kinase gene (PIK3CA)
are common in breast carcinoma, somatic mutations in AKTs are
rare [54,55]. Similarly we found only 1 of 47 cases exhibiting AKT-
1 mutation.
The presence of either high polysomy, low polysomy or
trisomy of EGFR does not appear to correlate with metastatic
disease (p=0.6, Figure 5). Five of the 8 cases (63%) with
detected mutations had metastatic disease, while 9 of the 28
cases (32%) with no mutations detected developed metastases;
however, there was no significant difference in metastasis-free
survival (p=0.12, Figure 4). Thus, there appears to be no
correlation between the presence of mutations and metastatic
disease. Apocrine-eccrine carcinomas and breast carcinomas are
analogous tumors often with similar histology. It is interesting
that in this study we detected mutations in PIK3CA and TP53 in
a subset of apocrine-eccrine carcinomas, a therapeutically-
Table 4. Summary of FISH and mutational analyses in apocrine-eccrine carcinomas.
EGFR FISH
polysomy
EGFR FISH
trisomy
EGFR FISH
polysomy/trisomy TP53 mutation
PIK3CA
mutation AKT-1 mutation
Apocrine carcinoma 1/7 0/7 1/7 0/5 0/5 0/5
Eccrine carcinoma 4/7 0/7 4/7 2/7 0/7 0/7
Aggressive digital papillary
adenocarcinoma
0/8 0/8 0/8 2/8 0/8 0/8
Hidradenocarcinoma 2/8 2/8 4/8 2/10 1/10 1/10
Porocarcinoma 2/9 1/9 3/9 0/11 2/11 0/11
Adenoid cystic carcinoma 0/1 0/1 0/1 0/1 0/1 0/1
Malignant chondroid syringoma 0/4 0/4 0/4 0/3 0/3 0/3
Malignant spiradenoma 1/1 0/1 1/1 0/1 0/1 0/1
Malignant cylindroma 0/1 1/1 1/1 1/1 0/1 0/1
Total 10/46 (21%) 4/46 (9%) 14/46 (30%) 7/47 (15%) 3/47 (6%) 1/47 (2%)
doi:10.1371/journal.pone.0047290.t004
Figure 3. Mutational profiling of apocrine-eccrine carcinoma
using SNaPshotH genotyping. The top panel shows genotypic data
obtained with normal male genomic DNA (Promega, Madison, WI, USA)
and the lower panel illustrates mutation detection in tumor DNA
derived from formalin-fixed paraffin-embedded specimens.
doi:10.1371/journal.pone.0047290.g003
Figure 4. Kaplan-Meier plot of metastasis-free survival time by
mutational analysis results (N=36). The plot shows the distribu-
tion of time from diagnosis to metastasis for patients with (n=8) and
without (n=28) one or more detected mutations, for whom follow-up
information is available (N=36). Patients who did not have metastases
are censored (indicated by vertical mark) at the time of the most recent
follow-up information.
doi:10.1371/journal.pone.0047290.g004
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frequently mutated in breast carcinomas.
Currently there is no uniform guideline concerning the
treatment for metastatic apocrine-eccrine carcinomas and
treatment success has been documented only in isolated case
reports [6–8]. A variety of chemotherapeutic agents have been
used with varying degrees of responsiveness. Combinations of
cyclophosphamide, bleomycin, cisplatin, and 5-fluorouracil;
interferon-alpha, interleukin-2, sunitinib, and tamoxifen have
been reported with some degree of response [6,8,56,57].
Remission was achieved for 16 months with paclitaxel and
carboplatin in a case of apocrine carcinoma with lymph node,
lung, and bone metastasis [58]. Hikada et al [59] reported a case
of metastatic apocrine carcinoma responded to treatment with
HER-2 inhibitors. Radiation therapy has been used in selected
cases of metastatic porocarcinoma [60].
In this study we used a SNaPshot platform, previously reported
by our group [24], to screen relevant cancer genes with available
targeted therapeutic agents in rare tumors. The platform is cost
effective due to two main reasons. First, SNaPshot testing uses
thermocyclers (PCR machines) and capillary electrophoresis DNA
sequencers, which are instruments that already exist in any typical
clinical molecular laboratory. Thus, there is not need for an
upfront investment in expensive equipment or bioinformatics
personnel. Secondly, because SNaPshot tests for hotspot mutations
in a multiplexed fashion, it only uses a fraction of tumor tissue
required for probing the same number of exons using Sanger
sequencing.
In summary, we report mutations in AKT-1, PIK3CA and
TP53 in a subset of apocrine-eccrine carcinomas including
eccrine carcinoma, aggressive digital papillary adenocarcinoma,
hidradenocarcinoma, and porocarcinoma. There is strong
correlation of AR expression in the apocrine carcinoma subtype,
raising the potential for anti-androgen therapy. The role of
EGFR inhibitor therapy in apocrine-eccrine carcinomas with
protein overexpression remains unclear. The lack of correlation
between the protein expression and polysomy/gene amplifica-
tion suggests that molecular mechanisms other than gene
amplification may play a role in EGFR overexpression in
adnexal carcinomas. Based on our findings, targeted therapy
including PI3K/Akt/mTOR pathway inhibitors, which is
currently in clinical testing, may be potential treatment options
for rare cases of apocrine-eccrine carcinomas. It will be
interesting to determine whether these results will translate into
real therapeutic response in followup clinical trial studies.
Figure 5. Kaplan-Meier plot of metastasis-free survival time by
EGFR FISH results (N=34). The plot shows the distribution of time
from diagnosis to metastasis for patients with (n=12) and without
(n=22) polysomy/trisomy for EGFR, for whom follow-up information is
available (N=34). Patients who did not have metastases are censored
(indicated by vertical mark) at the time of the most recent follow-up
information.
doi:10.1371/journal.pone.0047290.g005
Table 5. Summary of TP53 mutations in apocrine-eccrine carcinomas [15–19].
Case Histologic type TP53 mutation Reference
1 aggressive digital papillary adenocarcinoma Exon 8, Arg273His 16
2 Exon 8, Arg273Cys current study
3 eccrine carcinoma Exon 5, Cys176Arg 18
4 Exon 7, Arg248Gln 16
5 Exon 8, Arg273Cys 16
6 hidradenocarcinoma Exon 5, Cys176Tyr 15
7 Exon 7, Arg248Gln 15
8 Exon 8, Arg273His 17
9 Exon 6, Arg196X & Arg213X 17
10 Exon 8, Arg273Cys current study
11 Exon 8, Arg273Cys current study
12 malignant cylindroma Exon 8, Arg273His current study
13 Porocarcinoma Exon 8, codons 273–275, 9bp deletion 15
14 spiradenocarcinoma Exon 8, Glu285Lys 15
15 Exon 7, Arg248Gln 15
16 trichilemmal carcinoma Exon 8, codon 306, C R T1 9
doi:10.1371/journal.pone.0047290.t005
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